INVESTORS

A dedication to novel, life-changing therapeutics
An image of a woman staring at a large glass screen that is displaying text, numbers and graphs.
OVERVIEW

PYC Therapeutics is a clinical-stage biotech company that targets the underlying drivers of genetic diseases.

We combine scientific rigour, clinical insights and a proprietary drug delivery platform to treat genetic diseases for which there are limited, if any, treatment options available.

With a differentiated delivery technology that helps overcome the challenges faced by traditional RNA therapies we’re confident in our ability to deliver disease-modifying therapeutics to patients with no current treatment options.

View our analyst coverage, ASX announcements, posters & publications,
governance & policies and reports pages for more information.

 

Our strategic advantage

An overview of key opportunities.
An icon of a navy blue target with an arrow in the centre of it. There is an orange circle in the bottom left corner with a clear division sign within it.

A higher probability of clinical success

We have a focus on monogenic indications (diseases caused by a mutation in a single gene). These have the highest likelihood of approval from the start of clinical trials to market of any indication. Studies have shown that monogenic diseases have a 5x greater probability of achieving market entry compared to the industry average.1

An icon of a navy blue calendar with small orange clock in the bottom right corner.

A faster path to market

We target diseases that have no current treatment options available. This provides the potential for regulatory approval following two clinical trials (not three), representing a streamlined path to the development of a life-changing treatment for patients.

An icon of a bar graph with three navy blue bars increasing in size from left to right. There is a jagged orange trend line over the top of these bars that extends from the bottom left corner to the top right corner.

Likely rapid uptake in market

First-in-class drugs for rare diseases achieve rapid market penetration, with a very short lead time to peak sales. We target orphan (rare) diseases with markets in excess of $1 billion per annum, providing attractive shareholder returns.1

An icon of a navy blue price tag behind an orange price tag.

Orphan drug pricing

The median list price is ~$150,000 per patient per annum – this makes for commercially attractive markets across the pipeline.2

Investor spotlight

The key information to stay ahead.

ASX
$1.45
AUD
Share price
20 Dec 2024 05:10 UTC
ASX
$676.58M
AUD
Market capitalisation
20 Dec 2024 05:10 UTC
An image of a female scientist wearing a white lab coat and blue gloves. She is standing over a metal desk space and measuring fluid from a clear container using a white device.
Reports

Annual and interim reports

Review our latest corporate report

Read more
An image of a woman staring at a large glass screen that is displaying text, numbers and graphs.
Investors

Latest ASX
Announcements

Information for investors

Read more

Shareholder services

For enquiries relating to your shareholdings and to access your holding, please contact Automic Group:

Automic Group

Level 5, 191 St Georges Terrace

Perth WA 6000

T: 1300 2288 664 (within Australia)

T: +61 2 8072 1400 (globally)

SUBSCRIBE

Keep up with all the latest changes

    A photo of a female scientist wearing a white lab coat and blue gloves in a lab. She is placing a test tube inside a centrifuge.

    References

    1. Szustakowski JD, Balasubramanian S, Kvikstad E et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat Genet 2021;53:942–948. https://doi.org/10.1038/s41588-021-00885-0 ↩︎
    2. EvaluatePharma. Orphan Drug Report. 2019. ↩︎